

formance, co-occurring with positive functional changes in hemodynamic activity in regions involved in the memorization of associations.<sup>10</sup> Impaired associative memory is a hallmark of early stages of Alzheimer disease.

Exercise compliance was low, suggesting that we are providing conservative estimates of the efficacy of RT on cognition and functional plasticity. While the AT group had the highest dropout rate, they demonstrated a significant increase in general cardiovascular capacity. Our findings may not generalize to men or to women of other ages.

In conclusion, our study suggests that twice-weekly RT is a promising strategy to alter the trajectory of cognitive decline in seniors with mild cognitive impairment.

Lindsay S. Nagamatsu, MA  
Todd C. Handy, PhD  
C. Liang Hsu, BSc  
Michelle Voss, PhD  
Teresa Liu-Ambrose, PT, PhD

**Author Affiliations:** Departments of Psychology (Ms Nagamatsu and Dr Handy) and Physical Therapy (Mr Hsu and Dr Liu-Ambrose), University of British Columbia, Vancouver, British Columbia, Canada; The Brain Research Centre (Ms Nagamatsu, Drs Handy and Liu-Ambrose, and Mr Hsu) and The Centre for Hip Health and Mobility (Ms Nagamatsu, Mr Hsu, and Dr Liu-Ambrose), Vancouver Coastal Health Research Institute, Vancouver; and University of Illinois at Urbana-Champaign, The Beckman Institute for Advanced Science and Technology, Urbana (Dr Voss).

**Correspondence:** Dr Liu-Ambrose, Department of Physical Therapy, University of British Columbia, 212-2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada (tlambrose@exchange.ubc.ca).

**Author Contributions:** All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design:* Voss and Liu-Ambrose. *Acquisition of data:* Nagamatsu, Hsu, and Liu-Ambrose. *Analysis and interpretation of data:* Nagamatsu, Handy, Voss, and Liu-Ambrose. *Drafting of the manuscript:* Nagamatsu, Handy, and Liu-Ambrose. *Critical revision of the manuscript for important intellectual content:* Nagamatsu, Handy, Hsu, Voss, and Liu-Ambrose. *Statistical analysis:* Nagamatsu, Voss, and Liu-Ambrose. *Obtained funding:* Liu-Ambrose. *Administrative, technical, and material support:* Nagamatsu, Hsu, Voss, and Liu-Ambrose. *Study supervision:* Handy and Liu-Ambrose.

**Financial Disclosure:** None reported.

**Funding/Support:** The Pacific Alzheimer's Research Foundation provided funding for this study (Dr Liu-Ambrose).

**Previous Presentation:** Data from this manuscript were presented as a podium presentation at the International Society for Neuroimaging in Psychiatry; September 9, 2011; Heidelberg, Germany.

**Additional Information:** Ms Nagamatsu is a Michael Smith Foundation for Health Research Senior Graduate trainee and a Natural Sciences and Engineering Research Council of Canada Doctoral trainee. Dr Liu-Ambrose is a

Michael Smith Foundation for Health Research Scholar, a Canadian Institutes of Health Research New Investigator, and a Heart and Stroke Foundation of Canada's Henry J. M. Barnett's Scholarship recipient.


**Additional Contributions:** Alison Chan, BSc, Jennifer C. Davis, PhD, B. Lynn Beattie, MD, and Peter Graf, PhD, made significant contributions to this study. We thank the instructors for their commitment to the participants' health and safety.

1. Ferri CP, Prince M, Brayne C, et al; Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. *Lancet*. 2005;366(9503):2112-2117.
2. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol*. 1999;56(3):303-308.
3. Liu-Ambrose T, Nagamatsu LS, Graf P, Beattie BL, Ashe MC, Handy TC. Resistance training and executive functions: a 12-month randomized controlled trial. *Arch Intern Med*. 2010;170(2):170-178.
4. Liu-Ambrose T, Nagamatsu LS, Voss MW, Khan KM, Handy TC. Resistance training and functional plasticity of the aging brain: a 12-month randomized controlled trial [published online July 6, 2011]. *Neurobiol Aging*. doi:10.1016/j.neurobiolaging.2011.05.010.
5. Colcombe SJ, Kramer AF, Erickson KI, et al. Cardiovascular fitness, cortical plasticity, and aging. *Proc Natl Acad Sci U S A*. 2004;101(9):3316-3321.
6. Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. *Arch Neurol*. 2010;67(1):71-79.
7. Royall DR, Palmer R, Chiodo LK, Polk MJ. Declining executive control in normal aging predicts change in functional status: the Freedom House Study. *J Am Geriatr Soc*. 2004;52(3):346-352.
8. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005;53(4):695-699.
9. Spreen O, Strauss E. *A Compendium of Neurological Tests*. 2nd ed. New York, NY: Oxford University Press; 1998.
10. Herholz K, Ehlen P, Kessler J, Strotmann T, Kalbe E, Markowitsch H-J. Learning face-name associations and the effect of age and performance: a PET activation study. *Neuropsychologia*. 2001;39(6):643-650.

## Primary Care Providers' Response to the US Preventive Services Task Force Draft Recommendations on Screening for Prostate Cancer

In October 2011, the US Preventive Services Task Force (USPSTF) released draft recommendations for prostate cancer screening.<sup>1</sup> Prostate-specific antigen (PSA) testing was given a grade D, indicating that its use for routine screening should be discouraged. The draft recommendations contrast with those of the American Cancer Society and the American Urological Association.<sup>2,3</sup> In the context of competing recommendations and clinical uncertainty, our goals were to examine primary care providers' views of the draft recommendations and to determine to what extent they may be expected to change clinical practice.

**Methods.** A self-administered written survey was completed by practitioners in a university-affiliated practice, Johns Hopkins Community Physicians (JHCP). The JHCP is composed of 26 outpatient sites in 11 counties in Maryland. In 2010, approximately 40 000 men 40 years and older who were eligible for prostate cancer screening were seen at the JHCP. The survey was distributed at an annual organizational retreat. One hundred forty-one physicians and nurse practitioners who deliver primary care for adult male patients attended the retreat and



**Figure.** Percentage of providers who state that the US Preventive Services Task Force draft recommendations will change their prostate-specific antigen (PSA) screening practice according to how strongly they agree or disagree with the draft recommendations. The sample included providers who had previously heard of the draft recommendations (N=114).

were eligible to participate. The study was approved by the institutional review board of the Johns Hopkins University School of Medicine, Baltimore, Maryland.

**Results.** The response rate was 88.7%. Of the participants, 62.1% were female and 37.9% were nonwhite. With regard to training, 48.8% of the participants were internal medicine physicians, 39.0% were family practitioners, and 12.2% were trained in internal medicine and pediatrics. Most of them (67.5%) had finished residency more than 10 years earlier.

One hundred fourteen of 123 providers (92.7%) had heard about the USPSTF draft recommendations (2 had missing data and were excluded), and they comprise the sample for the remainder of the analyses. Approximately half of them (49.2%) agreed or strongly agreed that the recommendations were appropriate, while 36.0% disagreed or strongly disagreed; the remainder neither agreed nor disagreed. In response to the question, “How do you think the draft recommendations will change your approach to routine PSA screening?” a few providers (1.8%) said that they would no longer order routine PSA testing; 21.9% said that they would be much less likely to do so; 38.6% said that they would be somewhat less likely to do so; and 37.7% said that they would not change their screening practices. In bivariate analyses, agreement with the recommendations and expectations as to how the participants would change practice did not vary significantly by provider training (agreement,  $P=.38$ ; change practice,  $P=.91$ ), years since residency graduation (agreement,  $P=.73$ ; change practice,  $P=.36$ ), sex (agreement,  $P=.48$ ; change practice,  $P=.34$ ), or race/ethnicity (agreement,  $P=.48$ ; change practice,  $P=.33$ ).

Providers who agreed with the draft recommendations were significantly more likely to state that the recommendations would change their clinical practice (**Figure**) ( $P<.001$ ). However, even among those clinicians who agreed with the draft recommendations, fewer than half

(41.1%) stated that they would no longer order routine PSA screening or be much less likely to do so.

A total of 17.1% of providers said that over the past year they generally ordered PSA screening without discussing it with the patients, and 36.0% recommended PSA after discussing the benefits and harms with them. These clinicians were significantly less likely to state that the draft recommendations would cause them either to stop ordering PSA screening or to be much less likely to order PSA screening compared with clinicians who tended to let the patients decide on PSA screening after discussing the risks and benefits with them (11.9% vs 32.6%;  $P=.01$ ).

Providers were asked about barriers to stopping routine PSA screening among patients who had previously received screening (not specific to the draft recommendations). The most frequently endorsed barriers were that patients expected them to continue screening (74.6% agreed or strongly agreed), lack of time to explain changes (66.7%), fear of malpractice litigation (54.0%), and discomfort with uncertainty (42.5%). Relatively fewer providers worried that older patients would think they were trying to cut costs (26.6%) or that patients would think the providers were “giving up” on them (18.7%).

**Comment.** Of this diverse sample of primary care providers, nearly half agreed with the USPSTF draft recommendations. Fewer providers believed that the recommendations would lead them to stop ordering PSA screening. The clinicians who were most likely to believe that the draft recommendations would change their practice patterns were the providers who were least likely to report routinely ordering PSA tests in the preceding year. The results suggest that, if finalized, the USPSTF recommendations may encounter significant barriers to adoption. To the extent that PSA screening should be reduced, it may be necessary to address patient perceptions’ about screening, to allow adequate time for screening discussions, and to reduce concerns regarding malpractice litigation.

This survey has several possible limitations, including incomplete response, reliance on self-report to determine PSA screening patterns, and generalizability to other patient care settings and patient populations. Self-reported screening behavior was similar to findings from other samples,<sup>4</sup> and the overall rate of PSA testing in JHCP in 2010 (26.0% of patients >40 years of age) was the same as national screening rates.<sup>5</sup> The study was conducted shortly after the release of the draft recommendations and provides an important baseline about physician attitudes toward the draft recommendations and PSA screening.

Craig E. Pollack, MD, MHS  
 Gary Noronha, MD  
 Gene E. Green, MD  
 Nrupen A. Bhavsar, PhD, MPH  
 H. Ballentine Carter, MD

**Author Affiliations:** Division of General Internal Medicine (Drs Pollack and Bhavsar), Department of Pediatrics (Dr Bhavsar), and The James Buchanan Brady Urological Institute (Dr Carter), Johns Hopkins University School of Medicine, Department of Epidemiology, The Johns Hop-

kins Bloomberg School of Public Health (Drs Pollack and Bhavsar), and Johns Hopkins Community Physicians (Drs Noronha and Green), Baltimore, Maryland.

**Correspondence:** Dr Pollack, Division of General Internal Medicine, Johns Hopkins University School of Medicine, 2024 E Monument St, Room 2-615, Baltimore, MD 21287 (cpollac2@jhmi.edu).

**Author Contributions:** *Study concept and design:* Pollack, Noronha, Green, Bhavsar, and Carter. *Acquisition of data:* Pollack, Noronha, and Green. *Analysis and interpretation of data:* Pollack. *Drafting of the manuscript:* Pollack. *Critical revision of the manuscript for important intellectual content:* Pollack, Noronha, Green, Bhavsar, and Carter. *Statistical analysis:* Pollack. *Obtained funding:* Pollack and Carter. *Administrative, technical, and material support:* Pollack, Noronha, and Green. *Study supervision:* Noronha, Green, and Carter.

**Financial Disclosure:** Dr Pollack's salary was supported by a career development award from the National Cancer Institute and the Office of Behavioral and Social Sciences Research, National Institutes of Health (1K07CA151910-01A1). Dr Bhavsar's salary was supported by Agency for Healthcare Research and Quality grant T32HS019488. Ms Murphy received financial compensation from the Maryland Cigarette Restitution Fund.

**Funding/Support:** This study was supported in part by a Maryland Cigarette Restitution Fund Research Grant to the Johns Hopkins Institutions.

**Role of the Sponsor:** The Maryland Cigarette Restitution Fund had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

**Additional Contributions:** Elizabeth A. Platz ScD, MPH, contributed to the study design, survey development, data interpretation, and manuscript revision, and Erin Murphy and Sean Chen assisted with the survey.

1. Screening for prostate cancer: draft recommendation statement AHRQ publication No. 12-05160-EF-2. US Preventive Services Task Force Web site. <http://www.uspreventiveservicestaskforce.org/uspstf12/prostate/draftrec3.htm>. Accessed December 7, 2011.
2. Wolf AM, Wender RC, Etzioni RB, et al; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. *CA Cancer J Clin*. 2010;60(2):70-98.
3. Greene KL, Albersen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. *J Urol*. 2009;182(5):2232-2241.
4. Linder SK, Hawley ST, Cooper CP, Scholl LE, Jibaja-Weiss M, Volk RJ. Primary care physicians' reported use of pre-screening discussions for prostate cancer screening: a cross-sectional survey. *BMC Fam Pract*. 2009;10:19. doi:10.1186/1471-2296-10-19.
5. Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggen SE. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. *J Clin Oncol*. 2011;29(13):1736-1743.

## COMMENTS AND OPINIONS

### Coronary Artery Calcium Scanning and Conflicts of Interest

**C**oronary artery calcium (CAC) score and high-sensitivity C-reactive protein level are currently the leading contenders to join traditional risk factors in routine clinical assessment of

coronary heart disease risk. I do not believe that there is sufficient data to use either at present, and I read with interest the thoughtful critique of CAC scanning by Ridker.<sup>1</sup> No conflicts of interest are reported, but Ridker is a co-inventor on patents held by Brigham and Women's Hospital that use high-sensitivity C-reactive protein in assessing cardiovascular disease risk. Having a financial stake in a competitor of CAC scanning for coronary artery disease risk stratification is an important conflict of interest to share with readers.

Pieter A. Cohen, MD

**Author Affiliation:** Department of Medicine, Cambridge Health Alliance, Harvard Medical School, Cambridge, Massachusetts.

**Correspondence:** Dr Cohen, Department of Medicine, Cambridge Health Alliance, Harvard Medical School, 1493 Cambridge St, Cambridge, MA 02139 (Pieter\_cohen@hms.harvard.edu).

**Financial Disclosure:** None reported.

1. Ridker PM. Coronary artery calcium scanning in primary prevention: a conversation with cardiology fellows. *Arch Intern Med*. 2011;171(22):2051-2052.

### In reply

In my recent Commentary in the Archives on coronary artery calcium scanning,<sup>1</sup> there is no disclosure of my conflict of interest with regard to inflammatory biomarkers and cardiovascular disease because the commentary contains no discussion of this topic. However, as requested by Dr Cohen, my disclosure is provided below.

Paul M. Ridker, MD

**Author Affiliation:** Center for Cardiovascular Disease and Prevention, Brigham and Women's Hospital, Boston, Massachusetts.

**Correspondence:** Dr Ridker, Center for Cardiovascular Disease and Prevention, Brigham and Women's Hospital, 900 Commonwealth Ave E, Boston, MA 02215 (pridker@partners.org).

**Financial Disclosure:** Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women's hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Seimens.

1. Ridker PM. Coronary artery calcium scanning in primary prevention: a conversation with cardiology fellows. *Arch Intern Med*. 2011;171(22):2051-2052.

### Cardiac Implantable Electronic Devices: Prevention Starts From Ethics

**W**e read with interest the article by Sohail et al,<sup>1</sup> in which infections related to cardiovascular implantable electronic devices (CIEDs) were associated with substantial admission and long-term mortality. The importance of clinical and technical procedures for infection prevention was stressed in the "Comment" section and the related Commentary.<sup>2</sup> However, an additional major issue